BVXV实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (7 Sep 2023 @ 03:59):

Stats
今日成交量	22 668.00
平均成交量	38 939.00
市值	4.97M
EPS	ILS0 ( 2023-11-29 )
Last Dividend	ILS0 ( N/A )
Next Dividend	ILS0 ( N/A )
P/E	-0.579
ATR14	ILS0.0550 (6.88%)

Insider Trading

Date	Person	Action	Amount	type
2023-01-01	Margolin Yael	Sell	133 200	Restricted Share Units
2023-01-01	Margolin Yael	Sell	0	Ordinary Shares
2023-01-01	Laster Morris C	Sell	133 200	Restricted Share Units
2023-01-01	Laster Morris C	Sell	0	Ordinary Shares
2023-01-01	Lowell George	Sell	133 200	Restricted Share Units

INSIDER POWER
-100.00
Last 23 transactions
Buy: 0 \| Sell: 12 745 600

音量相关性

長: 0.06 (neutral)

短: -0.15 (neutral)

Signal:(16.452) Neutral

BiondVax Pharmaceuticals 相关性

10 最正相关
ODT	0.975
OPTN	0.97
TCDA	0.969
TTCF	0.966
STSA	0.962
FNWD	0.951
SNCE	0.95
PLXP	0.943
HIBB	0.938
AGRI	0.936

10 最负相关
BIOS	-0.955
CCRC	-0.955
SVFA	-0.95
OXUS	-0.943
SLAM	-0.942
SVFAU	-0.942
TZPSU	-0.941
ALPA	-0.94
COCO	-0.94
SCOB	-0.94

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

BiondVax Pharmaceuticals 相关性 - 货币/商品

-0.65
( weak negative )

-0.85
( strong negative )

0.64
( weak )

-0.77
( moderate negative )

0.52
( weak )

BiondVax Pharmaceuticals 财务报表

Annual	2022
营收:	ILS0
毛利润:	ILS0 (0.00 %)
EPS:	ILS0

FY	2022
营收:	ILS0
毛利润:	ILS0 (0.00 %)
EPS:	ILS0

FY	2021
营收:	ILS0.00
毛利润:	ILS0.00 (0.00 %)
EPS:	ILS-3.72

FY	2020
营收:	ILS0.00
毛利润:	ILS0.00 (0.00 %)
EPS:	ILS-4.02

Financial Reports:

No articles found.

BiondVax Pharmaceuticals

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.